Semaglutide and Menopause: What the Stage-by-Stage Data Shows

STEP UP was a Novo Nordisk phase 3b trial of a higher-strength version of branded Wegovy in adults with obesity and without diabetes, run for 72 weeks alongside a lifestyle program. The main results were published in The Lancet Diabetes & Endocrinology in 2025.

In May 2026, at the European Congress on Obesity, Novo Nordisk presented a post-hoc analysis that split the women in the higher-strength Wegovy arm by menopausal stage. According to the company's announcement, premenopausal women lost an average of 22.6% of their body weight, perimenopausal women 19.7% and postmenopausal women 19.8%. Waist circumference fell by 17.5%, 15.6% and 15.3% across the same three groups.

Those are figures for branded Wegovy in a Novo Nordisk trial. They are not figures for the compounded semaglutide ACT 2 prescribes, and nothing on this page should be read as a prediction of what any one person will lose.

The same announcement reported a post-hoc look at the SELECT cardiovascular trial in perimenopausal and postmenopausal women on branded Wegovy, with results consistent with the trial overall. The difference between the two menopause groups was not statistically significant, and the company said so. Our page on semaglutide and heart risk covers SELECT itself.

What it can. Menopausal stage did not appear to switch the drug off. Perimenopausal and postmenopausal women in the higher-strength Wegovy arm lost weight in the same broad range as each other, and the waist measurements moved with the scale. That is the first direct evidence for a question women have been asking for years.

What it cannot. Four limits are worth stating plainly.

• It is post-hoc. The trial was not designed to compare menopause stages. Subgroups carved out after the fact can suggest a pattern; they cannot prove one.
• It is not yet a full paper. At the time of writing the stage analysis exists as a conference presentation and a company press release, not a peer-reviewed article. The company reported the figures as the effect "if all people adhered to treatment," which tends to run higher than what happens in ordinary use.
• It is branded, higher-strength Wegovy. It is not compounded semaglutide, and it is not the strength most people have been prescribed. Our page on compounded semaglutide versus Wegovy explains why the two are not interchangeable.
• It does not test hormone therapy. The analysis sorted women by stage, not by whether they were on HRT. It says nothing about the combination.

The premenopausal group lost the most, and the company suggested that treating earlier might add to the effect. That is a hypothesis drawn from a subgroup, not a finding, and we would not start anyone on a GLP-1 sooner on the strength of it.

This is the question that matters most in practice, and the evidence is thinner than the interest.

Does HRT help or hinder? The most cited data is a 2024 Mayo Clinic retrospective study of postmenopausal women on semaglutide. The 16 women who were also on hormone therapy lost more weight at every checkpoint over a year than the 90 who were not. That is encouraging, and it is also a small, retrospective comparison. Women who choose HRT may differ in other ways from women who do not, so the study cannot show that the hormone therapy caused the difference. No randomized trial has tested the combination.

Do the two interact? GLP-1 medications slow the emptying of the stomach, and the Wegovy label advises caution with oral medications for that reason. In the label's pharmacology studies, semaglutide did not meaningfully change exposure to an oral contraceptive, but menopausal hormone therapy was not studied. For a woman on a GLP-1, that is one reason we favor transdermal estradiol, which does not pass through the gut at all. Our page on the estradiol patch on a GLP-1 sets out the full reasoning, including what it means for progesterone.

Which does what? They are not substitutes. Hormone therapy treats menopausal symptoms such as hot flashes and night sweats, and The Menopause Society describes the decision as an individual balance of benefits and risks. A GLP-1 is a weight and metabolic treatment. Our women's HRT page covers the hormone side; this page and the hub cover the weight side. For many women the right plan uses both, started in an order that lets each be judged on its own.

What we watch for. Symptoms returning in a woman who had been well controlled, timed to a change in the GLP-1. New or unexpected bleeding in a woman with a uterus. Nausea that makes an evening progesterone tablet hard to keep down. None is common; each is worth a message the day it happens.

A woman in perimenopause can still become pregnant. Menopause is defined as twelve months without a period, and until then contraception still matters. The Wegovy label says to stop the drug when pregnancy is recognized, because it may cause fetal harm. So in perimenopause the contraception conversation happens before the first prescription, not after a late period. Our page on whether you are in perimenopause helps place where you are.

Perimenopause also brings irregular bleeding of its own, which can blur the signals we listed above. That is a reason to keep both prescribers in the loop, not a reason to avoid treatment.

The general exclusions on the main page apply, including a personal or family history of medullary thyroid cancer or MEN 2. For side effects at the class level, see the GLP-1 side effects FAQ. After the menopause, muscle and bone become part of the plan; the muscle and bone page covers why.